Background-Recent genome-wide association studies in which selected community populations are used have identified genomic signals in SCN10A influencing PR duration. The extent to which this can be demonstrated in cohorts derived from electronic medical records is unknown. Methods and Results-We performed a genome-wide association study on 2334 European American patients with normal
W idely used ECG parameters, such as PR and QT intervals, display substantial variability when measured across large populations. 1, 2 Some of this variability reflects underlying disease and concomitant drug therapy, but even after correction for these, such variability persists. Thus, for example, we have recently reported that the 99% confidence interval for PR was 120 to 206 ms in a set of Ͼ30 000 ECGs studied in normal individuals in our electronic medical records (EMR). 3 
Clinical Perspective on p 2021
One extensively studied ECG measurement is the QT interval. Variability in the QT interval is a marker for sudden cardiac death not only in patients with congenital and drug-associated long-QT syndromes 4, 5 but also in more general settings, notably after myocardial infarction. 6 An initial genome-wide association study (GWAS) of variability in the QT interval across large populations identified variants at chromosome 1 near NOS1AP as contributors. 7 Subsequently, with accrual of larger numbers of subjects and meta-analyses, multiple loci at which genomic variants contribute to variability in QT interval have been identified. 8, 9 Some of these are located in genes well known to modulate cardiac repolarization, such as those encoding cardiac ion channels, whereas the relationship of others to normal QT intervals is less clear. Thus, genome-wide approaches can uncover new pathways in pathophysiology. Indeed, variants in NOS1AP have now been implicated as predictors of sudden cardiac death in large populations. 10, 11 Most recently, 3 groups reported the results of GWAS evaluating atrioventricular conduction (the PR interval). [12] [13] [14] Multiple loci were implicated, and all 3 studies converged on variants in SCN10A. Interestingly, SCN10A is located on chromosome 3 adjacent to SCN5A, which encodes the major cardiac sodium channel gene in heart, but SCN10A had not, to date, been implicated as a modulator of cardiovascular physiology.
These results were obtained by analysis of large cohorts of patients recruited from communities or specific clinics for epidemiological study. We and others 15, 16 have proposed an alternate strategy, in which DNA repositories are linked to EMR across large healthcare systems. Theoretical advantages of this paradigm are rapid generation of patient sets for study (because electronic data are already in place) and the ability to study large numbers of subjects accrued without bias with respect to factors such as disease or age. However, despite these theoretical advantages, the utility of EMR-based approaches for validation or discovery of genotype-phenotype associations in populations remains largely unexplored.
The National Human Genome Research Institute's electronic MEdical Records and GEnomics (eMERGE) Network has as one of its primary goals the evaluation of the utility of EMR systems coupled to DNA repositories as a tool for genome science. We report here the development of algorithms to identify subjects with normal PR intervals who lack heart disease. A subset of this population has been accrued into BioVU, the Vanderbilt DNA databank, 15 and has undergone eMERGE-supported genome-wide genotyping, allowing us to evaluate the extent to which recently reported PR signals can be replicated in an EMR environment.
Methods

BioVU Design
The design of BioVU, which links DNA extracted from discarded blood samples to a deidentified image of the EMR, called the Synthetic Derivative, has been described previously. 15 BioVU accrues DNA samples extracted from blood remaining from routine clinical testing after it has been retained for 3 days and is scheduled to be discarded. The resource contains data and tissues that are deidentified in accordance with provisions of Title 45 Code of Federal Regulations part 46 that define criteria for investigations that are considered "nonhuman subjects" research. Exclusion criteria are poor quality or insufficient DNA; age Ͻ18 years; absence of a signed consent to treatment form; an individual who has opted out; and duplicate samples. In addition, a small percentage of patients (Ϸ2%) is randomly excluded from BioVU so that it is not possible to know whether any individual's sample is or is not included in the biobank. The project has been reviewed at multiple levels, including the institutional review board, internal and external ethics committees, Community Advisory Board, legal department, and the federal Office of Human Research Protection, and this oversight is ongoing. 17 As of May 10, 2010, BioVU included samples from 84 540 individuals. Preliminary studies genotyped the initial 10 000 subjects accrued at Ϸ100 single nucleotide polymorphisms (SNPs) previously associated with common diseases; natural language processing (NLP) techniques were developed and validated to identify cases and controls for 5 common diseases, and previously reported genotypephenotype associations were replicated. 18 In the present report, we developed and validated NLP approaches to identify subjects with normal ECGs and no evidence of heart disease at the time of the ECG. A subset of these records is linked to eMERGE-supported Illumina 660W-Quad genotyping, and the results of the PR analysis are presented here.
Identifying the Case Population
Subjects were selected by analyzing records in the Synthetic Derivative, which is a deidentified image of the EMR linked to BioVU by research unique identifiers generated by hashing the medical record number. 15 The Vanderbilt EMR began accumulating data in the early 1990s and now include all inpatient and outpatient billing codes, laboratory values, reports, and clinical documentation, almost all in electronic formats available for searching. It currently contains Ͼ120 million documents on Ϸ2 million patients. The Synthetic Derivative is refreshed regularly to add new clinical information from the EMR as it is accrued.
The study population consisted of subjects with a normal ECG without evidence of cardiac disease before or within 1 month after the ECG, with concurrent use of medications that interfere with ventricular conduction, and who did not have abnormal potassium, calcium, or magnesium laboratory values at the time of the ECG. The algorithm combined NLP 19, 20 to analyze unstructured text, billing code queries, and laboratory queries to exclude any subjects with evidence of arrhythmia, heart failure, cardiomyopathy, myocardial ischemia/infarct, or cardiac conduction defect. The algorithm considered all physician-generated clinical documentation, including clinical notes and cardiologist-generated ECG impressions. Patients with family histories of cardiac disease or who were allergic to restricted medications were allowed by the NLP algorithm. In addition, the algorithm selected only patients whose ECGs had normal Bazett corrected QT intervals (Ͻ450 ms), heart rates (50 to 100 bpm), and QRS (65 to 120 ms). To ensure sufficient record size, we required each subject to have at least 1 clinical note. The study included only individuals designated as "non-Hispanic white" European American; we have shown a high degree of concordance between EMR ancestry designation and genetic ancestry determined from ancestry-informative markers in BioVU. 21, 22 We noted the presence or absence of concurrent medications that could affect atrioventricular conduction, including digoxin, nondihydropyridine calcium channel blockers, tricyclic antidepressants, and ␤-blockers. Measurements for the PR interval were taken from those stored in the EMR as produced by the ECG machine. All ECGs were processed with the use of Philips TraceMaster ECG software (Andover, Mass).
Two physicians not associated with algorithm development reviewed algorithm results with access to the entire deidentified medical records of the patients. The results of the manual classification were then used to improve the algorithms, and the procedure was iterated until the positive predictive value reached the predesignated target of Ն95% for a random selection of 100 subjects. In each iteration, the physicians reviewed a different set of 100 randomly selected subjects. The time between generation of the initial algorithm and its finalization was Ϸ6 weeks; identification of the final study set with the use of the algorithm took 6 computational hours. Complete details of the algorithm are available from http://gwas.net.
Genotyping and Data Analysis
Genotyping was performed at the Center for Genotyping and Analysis at the Broad Institute with the use of the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561 490 SNPs and 95 876 intensity-only probes. Data were cleaned with the use of the quality control (QC) pipeline developed by the eMERGE Genomics Working Group. This process includes evaluation of sample and marker call rate, gender mismatch and anomalies, duplicate and HapMap concordance, batch effects, Hardy-Weinberg equilibrium, sample relatedness, and population stratification. Relat- 
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edness was determined on the basis of identical by descent estimates generated from the genome-wide genotype data in PLINK. Individuals with an identical by descent estimate of Ͼ0.0625 were identified (4 sib pairs, 7 parent-child pairs, and 1 trio); 1 individual from each related pair and the child from the trio were removed from the analysis (12 total individuals removed). After QC, 514 999 SNPs were used for analysis based on the following QC criteria: SNP call rate Ͼ99%, sample call rate Ͼ99%, minor allele frequency Ͼ0.01, 99.99% concordance rate in duplicates, unrelated samples only, and individuals of European descent only (based on STRUCTURE 23 analysis of Ͼ90% probability of being in the CEU [Centre d'Etude du Polymorphisme Humain Utah residents with ancestry from Northern and Western Europe] cluster); our post-QC genomic control was ϭ1.011. We did not filter SNPs on the basis of deviation from Hardy-Weinberg equilibrium because this can be an indication of either true association or genotyping error. As such, we flagged all markers with Hardy-Weinberg equilibrium PϽ1ϫ10
Ϫ4 for further evaluation after analysis. All genotype data and a detailed QC report have been uploaded to dbGaP. The QC and data analysis were performed with a combination of PLINK and R.
Single-locus tests of association were performed by linear regression with assumption of an additive genetic model for all 514 999 SNPs in a total of 2334 individuals with a measured PR interval. All analyses were performed unadjusted and adjusted for age, sex, exposure to medications that may alter the PR interval, and the first 3 principal components from Eigenstrat to adjust for potential population stratification.
Results
Our algorithm identified 2334 European American individuals with genotyping data that passed QC ( Table 1 ). The positive predictive value for the final algorithm was 97%, including absence of all exclusion criteria. Patients had a median age of 55 years (interquartile range, 44 to 64 years; range, 19 to 98 years) and a median PR interval of 156 ms (interquartile range, 145 to 170 ms; range, 112 to 224 ms). Table 2 shows the results of linear regression analyses (including age, sex, PR-active drugs, and the first 3 principal components from Eigenstrat) that examined replication of the 3 published GWAS 12-14 of PR interval. The top SNPs for each of these 3 published analyses (14 total SNPs combined) are presented with the corresponding P values in the present analysis; 6 of 14 of these had P values Ͻ0.02 (all SNPs had similar minor allele frequency, effect size, and effect direction compared with the associations in the literature; data not shown). In the full adjusted linear regression analysis, we identified 4 SNPs in linkage disequilibrium with one another in the gene SCN10A that are associated with PR interval (Figure) : intronic rs7430477 (Pϭ1.78ϫ10 Ϫ6 ), missense (V1073A) rs6795970 (Pϭ7.26ϫ10 Ϫ7 ), intronic rs6800541 (Pϭ5.73ϫ10 Ϫ7 ), and intronic rs6798015 (Pϭ1.36ϫ10 Ϫ6 ). SCN10A was also associated in the unadjusted analysis (top SNP P value 5.18ϫ10 Ϫ7 ). The effect size (beta) is reported in milliseconds per copy of the minor allele. For the primary adjusted analysis, the top SNP (rs6800541) has a 2.517-ms change in PR interval per copy of the minor allele. This is slightly smaller than in the findings of Pfeufer et al, 12 in which beta is 3.7687 ms, as expected from the "winner's curse." 24 The percentage of variance in the PR interval explained by each of the 4 SCN10A SNPs above was Ϸ1% in the unadjusted model. The adjusted model, including SNP, age, sex, use of PR-active medications, and the first 3 principal components, explained Ϸ11% of the variance in PR duration. Table 3 lists all SNPs with a P value Ͻ10 Ϫ5 in the adjusted and unadjusted analyses including all subjects. Two of these CI indicates confidence interval. *All analyses for this study are calculated by linear regression adjusted for age, sex, use of PR-active medications, and the first 3 principal components from Eigenstrat.
†SNP not present in our data set.
(rs6795970 and rs6800541) were also identified in the 3 previously reported analyses. 12-14
Discussion
We demonstrate here that a population identified by interrogation of a deidentified version of an EMR system that has been organized for research purposes can be used to efficiently identify genomic determinants of PR interval. Although the number of subjects studied is relatively small compared with those in the recent GWAS, 12-14 the SCN10A signal, on which all 3 previous studies converged, is also seen in this analysis at significance levels of 10 Ϫ6 to 10 Ϫ7 . Subsequently, 3 additional loci implicated in the published PR GWAS were replicated in this data set at PϽ0.02. Although these do not meet a conventional definition of genome-wide significance, the significance threshold in a replication study is often relaxed, especially when the replication sample size is significantly smaller than the discovery cohort. On the basis of the sample size in the published literature (10 000 individuals), 13 using the effect size and allele frequency in BioVU, we achieve 99.99% power to detect the same effect at PϽ5ϫ10 Ϫ8 in SCN10A, ARGHGAP24, CAV1-CAV2, and TBX5. Thus, we expect that if we had 10 000 individuals in the BioVU set with EMR-derived PR duration, we would have identified nearly all PR-associated variants that were discovered previously in population-based or community-based cohorts.
The major result was similar irrespective of whether age, sex, concomitant medications, and principal component adjustments were made. It was also similar in analyses that excluded patients on medications known to influence atrioventricular conduction. The latter result may seem surprising in light of the fact that PR intervals were longer in those on versus off medications (163Ϯ19 versus 157Ϯ17 ms); however, this can be explained by noting that the relationships between PR predictive polymorphisms and medication use were very weak. Thus, in these data, medication use does not mediate the SNP-PR interval relationship in an obvious way. Accordingly, in cases such as these, analyses that include medicated patients for GWAS will often be more powerful than those that do not.
In this study, we used NLP approaches to identify a study set lacking potential confounders such as heart disease that would increase experimental noise. Despite this inclusion, we were readily able to identify sufficient samples for study because the pool from which the samples were drawn is very large. Using EMR in genomic research allows study of large populations without overt or hidden biases relative to inclusion criteria that are often part of recruitment into clinical trials. Population-based epidemiological cohorts lack such bias but may have fewer data with respect to long-term outcomes across all disciplines. Nevertheless, the attraction of EMR as a research tool in genomic science is only now beginning to be explored. In a previous study, we showed that well-studied SNPs associated with atrial fibrillation, rheumatoid arthritis, Crohn's disease, multiple sclerosis, and type 2 diabetes mellitus could be replicated in the initial 10 000 subjects accrued into BioVU. 18 The generalizability of any result such as this, from an EMR or other source such as a community cohort or a clinical trial, may be limited if the recruitment is in some fashion biased. The fact that we identify a locus implicated in recent GWAS analyses speaks further to the generalizability of this result.
One obstacle to this use of EMR is the need to develop and validate algorithmic approaches to identify study subjects and controls, if needed. This study required a combined approach of NLP, laboratory queries, identification of prescribed medications, and billing code queries to achieve a high positive predictive value while capturing a sufficiently large case population. The availability of large EMR, with long follow-up (a median of 5 years in BioVU), offers potential for reuse of genotype data for subsequent analyses of other phenotypes. Developing sets of validated phenotype selection algorithms and assessing the extent to which these apply across EMR systems are goals of the eMERGE network. This GWAS and previous ones identify a gene heretofore not implicated in cardiac pathophysiology as a modulator of PR interval in humans. Further studies are required to identify the role of SCN10A variants in normal and abnormal atrioventricular nodal function. Other genetic loci identified in previous studies, as well as this one, await further replication studies.
